Eyonis Inc. unveils promising results from eyonis® LCS at CHEST 2026

eyonis Inc., a subsidiary of Median Technologies, presented significant results for its eyonis® LCS software at the CHEST 2026 conference. This software, designed for lung cancer screening, demonstrated a sensitivity of 93.3%, a specificity of 92.4%, and a negative predictive value of 99.9%. This medical device, based on artificial intelligence, is FDA-approved for its dual computer-aided detection and diagnostic capabilities.

Participation in CHEST 2026 allows Median Technologies to strengthen its ties with pulmonologists, key players in the adoption of new AI solutions. The eyonis® LCS booth attracted attention, illustrating its contribution to reducing false negatives and positives in lung screening.